India revokes local cancer drug patent

2013-08-02 21:06

(Shutterstock) (Shutterstock)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

New Delhi - India has revoked a local patent granted to Britain's GlaxoSmithKline for a breast cancer drug in the latest blow to companies seeking a bigger presence in the country's $13bn medicine market.

Tykerb, one of the most widely prescribed breast cancer treatments in India used to treat advanced forms of the disease, is a newer version of GlaxoSmithKline's (GSK) original anti-breast cancer drug lapatinib.

The Indian patent board revoked the patent for Tykerb, calling it an incremental improvement of the original compound and not sufficiently innovative to warrant a patent.

The ruling underscores Indian authorities' tough stance against what is called "evergreening" or minor changes to a drug to extend its patent shelf life, said Dominc Alvares, the lawyer who was part of the team which challenged GSK's Tykerb patent.

"India has some of the toughest patent laws - and they are based on public interest," Alvares, of S Majumdar and Co, told AFP.

Once drugs go off patent, they can be sold more cheaply.

GSK had argued that Tykerb delivered a better "therapeutic" effect than its predecessor.

"We are disappointed that the patent board has revoked our patent for the lapatinib ditosylate salt (Tykerb)," a company official said in an emailed message.

"Intellectual property protection is an important aspect in ensuring innovation is encouraged and appropriately rewarded," the official added, asking not to be named.

Western drug-makers are seeking to win a larger part of India's rapidly expanding drugs market, valued at around $13bn.

Pharmacy to the world

But they say that India, known as the "pharmacy to the world" for its huge generics industry that turns out copycat versions of branded drugs, fails to respect intellectual property rights.

India's law restricts pharmaceutical companies from seeking fresh patents for making minor modifications.

The Tykerb ruling comes after the Supreme Court in April struck down a patent for an updated version of Swiss giant Novartis's blockbuster leukaemia drug Glivec.

Novartis had argued the compound was a significant improvement because it is more easily absorbed by the body but the court said it did not pass the test of innovation.

Experts then said the court ruling could pave the way for a rush of similar Indian rulings.

GSK is considering an appeal of the decision "to validate this patent", said the company official.

The ruling only affects the new patent, not the original patent for the main active ingredient in the drug, lapatinib, which expires in 2019.

Read more on:    glaxosmithkline  |  india  |  health

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.
NEXT ON NEWS24X publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.